Recent advances in transfusions in neonates/infants

• Type of Material: Article
• Authors: Ruchika Goel, New York Presbyterian Hospital; Cassandra D Josephson, Emory University
• Language: English
• Date: 2018-01-01
• Publisher: F1000Research
• Publication Version: Final Published Version
• Copyright Statement: © 2018 Goel R and Josephson CD.
• License: Creative Commons Attribution 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.12688/f1000research.13979.1
• Title of Journal or Parent Work: F1000Research
• ISSN: 2046-1402
• Volume: 7
• Keywords: Transfusion; Plasma; Neonates; Children; Platelets; Pediatrics; Premature Infants; Preemies; Infants; Red Blood Cells
• Research Categories: Health Sciences, Medicine and Surgery; Health Sciences, Oncology

Abstract

Transfusions of red blood cells (RBCs), platelets, and plasma are critical therapies for infants and neonates (particularly preterm neonates) in the neonatal intensive care unit, who are the most frequently transfused subpopulation across all ages. Although traditionally a significant gap has existed between the blood utilization and the evidence base essential to adequately guide transfusion practices in infants and neonates, pediatric transfusion medicine is evolving from infancy and gradually coming of age. It is entering an exciting era with recognition as an independent discipline, a new and evolving high-quality evidence base for transfusion practices, novel technologies and therapeutics, and national/international collaborative research, educational, and clinical efforts. Triggers and thresholds for red cell transfusion are accumulating evidence with current phase III clinical trials. Ongoing trials and studies of platelet and plasma transfusions in neonates are anticipated to provide high-quality evidence in years to come. This article aims to summarize the most current evidence-based practices regarding blood component therapy in neonates. Data on the use of specific components (RBCs, plasma, and platelets) are provided. We attempt to define thresholds for anemia, thrombocytopenia, and abnormal coagulation profile in neonates to highlight the difficulties in having a specific cutoff value in neonates and preterm infants. Indications for transfusion of specific products, transfusion thresholds, and current practices and guidelines are provided, and possible adverse outcomes and complications are discussed. Finally, the critical research knowledge gaps in these practices as well as ongoing and future research areas are discussed. In an era of personalized medicine, neonatal transfusion decisions guided by a strong evidence base must be the overarching goal, and this underlies all of the strategic initiatives in pediatric and neonatal transfusion research highlighted in this article.